Note 2 - Going Concern and Liquidity	3 Months Ended
Mar. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 - GOING CONCERN AND LIQUIDITY The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception. At March 31, 2020, the Company’s cash on hand was approximately $766,000. Based on the expected cash needed for operating activities, the Company’s current cash and liquidity is not considered sufficient to finance the operating requirements for at least the next 12 months from the filing date of this report. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. In April 2020, the company announced an underwritten offering of 4,750,000 shares of its common stock and warrants to purchase up to an aggregate of 2,375,000 shares of the its common stock. for net proceeds of approximately $4.7 million. See Note 14. In addition, Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, as well as considering other strategic plans or transactions. However, as described in Note 1, the COVID- 19 pandemic is expected to have an adverse effect on the Company’s operations and cash flows for at least the next two quarters and possibly longer depending on the length and severity of the pandemic in important dental markets. Management is actively pursuing additional financing and/or other strategic plans and transactions but can provide no assurances that such financing or other strategic plans will be available on acceptable terms, or at all. Further, the extreme volatility in the financial markets due to COVID- 19, as well as the expected non-compliance with the NYSE May 20 th , 2020 requirement (Note 1 ) may make it more difficult to raise sufficient capital when needed or execute other strategic plans or transactions. These condensed consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recover ability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern.

NOTE

- GOING CONCERN AND LIQUIDITY

The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within

one

year after the date that these condensed consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception. At

March 31, 2020,

the Company’s cash on hand was approximately

$766,000.

Based on the expected cash needed for operating activities, the Company’s current cash and liquidity is

not

considered sufficient to finance the operating requirements for at least the next

months from the filing date of this report. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

April 2020,

the company announced an underwritten offering of

4,750,000

shares of its common stock and warrants to purchase up to an aggregate of

2,375,000

shares of the its common stock. for net proceeds of approximately

$4.7

million. See Note

14.

In addition, Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, as well as considering other strategic plans or transactions. However, as described in Note

the COVID-

pandemic is expected to have an adverse effect on the Company’s operations and cash flows for at least the next

two

quarters and possibly longer depending on the length and severity of the pandemic in important dental markets. Management is actively pursuing additional financing and/or other strategic plans and transactions but can provide

assurances that such financing or other strategic plans will be available on acceptable terms, or at all. Further, the extreme volatility in the financial markets due to COVID-

19,

as well as the expected non-compliance with the NYSE

May 20

2020

requirement (Note

)

may

make it more difficult to raise sufficient capital when needed or execute other strategic plans or transactions.

These condensed consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do

not

include any adjustments to reflect the possible future effects on the recover ability and classification of assets or the amounts and classification of liabilities that

may

result from the inability of the Company to continue as a going concern.